UK Notified Body BSI Sets Out Clear Post-Brexit Paths As It Goes Dutch
UK Notified Body BSI Sets Out Clear Post-Brexit Paths As It Goes Dutch
$200.00
Leading UK and EU notified body BSI expects the UK to remain a full member of the EU regulatory regime post-Brexit, but it has a contingency plan. Learn what this contingency plan means for device manufacturers. Gain insights into the implications of a non-negotiated Brexit, and find out if the other notified bodies have contingency plans.
Publisher: Medtech
- Description
Leading UK and EU notified body BSI plans to strengthen its position regardless of how Brexit plays out. It expects the UK to remain a full member of the EU regulatory regime post-Brexit, but it’s not taking any chances. In the event of a non-negotiated exit, BSI intends to migrate its clients to its parallel Netherlands-based notified body. What will this contingency plan entail for device manufacturers? Find out, and gain broader insights into the implications of a hard Brexit. Discover if the other notified bodies have similar contingency plans. If your device company does business in the UK, this is a must-read.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Infographic – 2018 Pharma Pipeline Snapshot 
Sign up to the